Panobinostat: a review of trial results and future prospects in multiple myeloma

Area of Science:

• Oncology
• Hematology
• Epigenetics

Background:

• Multiple myeloma is the second most common hematologic malignancy, accounting for 1-2% of all cancers.
• While therapies have doubled life expectancy, all patients eventually relapse, necessitating novel treatment approaches.
• Current treatments include immunomodulatory drugs and proteasome inhibitors, but breakthroughs are still needed.

Purpose of the Study:

• To explore the potential of epigenetic treatments in advancing multiple myeloma therapy.
• To investigate the role of histone acetylation in oncogene regulation within multiple myeloma.
• To evaluate the therapeutic potential of histone deacetylase inhibitors, specifically panobinostat.

Main Methods:

• Review of current literature on multiple myeloma treatments and epigenetic mechanisms.
• Analysis of the role of protein acetylation in chromatin accessibility and gene transcription.
• Discussion of histone deacetylase inhibitors as a potential therapeutic strategy.

Main Results:

• Epigenetic modifications, particularly histone acetylation, can influence oncogene expression in multiple myeloma.
• Histone deacetylase inhibitors can modulate epigenetic responses, potentially overcoming treatment resistance.
• Panobinostat represents a class of drugs with potential to alter the epigenetic landscape in cancer cells.

Conclusions:

• Epigenetic therapies offer a promising avenue for overcoming treatment resistance in multiple myeloma.
• Targeting histone acetylation with drugs like panobinostat could provide a novel therapeutic strategy.
• Further research into epigenetic modifications is crucial for developing more effective multiple myeloma treatments.